Researchers performed comprehensive multi‑omic profiling after transplanting a genetically edited pig kidney into a brain‑dead human donor and tracked immune dynamics over 61 days. The team identified antibody‑ and T‑cell‑driven rejection pathways and successfully reversed rejection episodes with combinations of FDA‑approved immunomodulatory drugs. Published in Nature, the analyses traced day‑by‑day immune cell infiltration and gene expression across human and pig tissues, revealing actionable targets to prevent or treat xenograft rejection. Authors included surgeons and immunologists who emphasize the translational value of prolonged sampling that isn’t feasible in living patients. The work advances xenotransplantation from proof‑of‑concept toward clinical readiness by defining immunologic checkpoints and demonstrating reversible rejection with existing agents.